Persistence with denosumab and persistence with oral bisphosphonates for the treatment of postmenopausal osteoporosis: a retrospective, observational study, and a meta-analysis.
作者： L. Karlsson , J. Lundkvist , E. Psachoulia , M. Intorcia , O. Ström
DOI: 10.1007/S00198-015-3253-4
关键词:
摘要: Summary The objectives of this study were to estimate persistence with denosumab and put these results in context by conducting a review oral bisphosphonates. Persistence was found be higher than
scienceopen.com
springer.com
paperity.org参考文章(66)
P. Hadji, N. Papaioannou, E. Gielen, M. Feudjo Tepie, E. Zhang, I. Frieling, P. Geusens, P. Makras, H. Resch, G. Möller, L. Kalouche-Khalil, A. Fahrleitner-Pammer, Persistence, adherence, and medication-taking behavior in women with postmenopausal osteoporosis receiving denosumab in routine practice in Germany, Austria, Greece, and Belgium: 12-month results from a European non-interventional study Osteoporosis International. ,vol. 26, pp. 2479- 2489 ,(2015) , 10.1007/S00198-015-3164-4
Yihua Xu, Hema N. Viswanathan, Melea A. Ward, Brad Clay, John L. Adams, Bradley S. Stolshek, Joel D. Kallich, Shari Fine, Kenneth G. Saag, Patterns of osteoporosis treatment change and treatment discontinuation among commercial and Medicare Advantage Prescription Drug members in a national health plan Journal of Evaluation in Clinical Practice. ,vol. 19, pp. 50- 59 ,(2013) , 10.1111/J.1365-2753.2011.01766.X
Geralamo Bianchi, Andrea Giusti, Treatment of primary osteoporosis in men Clinical Interventions in Aging. ,vol. 10, pp. 105- 115 ,(2014) , 10.2147/CIA.S44057
F.-E. Cotté, P. Fardellone, F. Mercier, A.-F. Gaudin, C. Roux, Adherence to monthly and weekly oral bisphosphonates in women with osteoporosis Osteoporosis International. ,vol. 21, pp. 145- 155 ,(2010) , 10.1007/S00198-009-0930-1
Evelina Tacconelli, Systematic reviews: CRD's guidance for undertaking reviews in health care Lancet Infectious Diseases. ,vol. 10, pp. 226- ,(2010) , 10.1016/S1473-3099(10)70065-7
D. Weycker, D. Macarios, J. Edelsberg, G. Oster, Compliance with drug therapy for postmenopausal osteoporosis. Osteoporosis International. ,vol. 17, pp. 1645- 1652 ,(2006) , 10.1007/S00198-006-0179-X
Tjeerd Van Staa, Arlene M Gallagher, Stephan Rietbrock, Melvin Olson, Tjeerd P van Staa, Fracture Outcomes Related to Persistence and Compliance With Oral Bisphosphonates Journal of Bone and Mineral Research. ,vol. 23, pp. 1569- 1575 ,(2008) , 10.1359/JBMR.080510
J. C. Lo, A. R. Pressman, M. A. Omar, B. Ettinger, Persistence with weekly alendronate therapy among postmenopausal women Osteoporosis International. ,vol. 17, pp. 922- 928 ,(2006) , 10.1007/S00198-006-0085-2
S. L. Silverman, E. Siris, D. L. Kendler, D. Belazi, J. P. Brown, D. T. Gold, E. M. Lewiecki, A. Papaioannou, C. Simonelli, I. Ferreira, A. Balasubramanian, P. Dakin, P. Ho, S. Siddhanti, B. Stolshek, C. Recknor, Persistence at 12 months with denosumab in postmenopausal women with osteoporosis: interim results from a prospective observational study. Osteoporosis International. ,vol. 26, pp. 361- 372 ,(2015) , 10.1007/S00198-014-2871-6
Deborah T. Gold, Bradley C. Martin, Jennifer R. Frytak, Mayur M. Amonkar, Felicia Cosman, A claims database analysis of persistence with alendronate therapy and fracture risk in post-menopausal women with osteoporosis. Current Medical Research and Opinion. ,vol. 23, pp. 585- 594 ,(2007) , 10.1185/030079906X167615